Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Share News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.536
Bid: 1.50
Ask: 1.58
Change: 0.011 (0.72%)
Spread: 0.08 (5.333%)
Open: 1.50
High: 1.536
Low: 1.50
Prev. Close: 1.525
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Liontrust shareholders upset; RTW adds to portfolio

Wed, 16th Feb 2022 22:06

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Wednesday and not separately reported by Alliance News:

----------

Liontrust Asset Management PLC - FTSE 250-listed London-based investment fund manager - Nearly 46% of shareholders vote against company's director remuneration policy at general meeting on Wednesday. Over 44% vote against adoption of the LTIP plan rules. "While the two resolutions were passed, the Remuneration Committee is acutely conscious of the votes against and will reflect on feedback from those shareholders. The company will continue its policy of full transparency with proactive engagement with its shareholders on aspects of remuneration going forward. In line with the UK Corporate Governance Code, we will provide an update within six months of this general meeting," company says. Notes it "undertook extensive and positive engagement" with its top 20 shareholders on the pay proposals ahead of the meeting.

----------

RTW Venture Fund Ltd - New York-based investor in life sciences, biopharmaceutical, and medical technology companies - Confirms participation in Series B financing round for Third Harmonic Bio Inc. Third Harmonic Bio completes USD50 million Series A financing and USD105 million Series B financing. "Third Harmonic Bio is a privately held clinical-stage biotechnology company developing a first-in-class, selective, oral KIT inhibitor for the treatment of severe allergy and inflammation. The proceeds from the financing rounds are expected to fund development of the company's lead candidate, THB001, through the next phase of human studies."

----------

Brunner Investment Trust PLC - London-based investment firm - Net asset per share ends November 30, 2021 at 1,176.9 pence versus 988.7p at same point year before. "Stock markets in 2021 witnessed strong returns, led by the US and Europe, interspersed with bouts of volatility. Against this backdrop, we are pleased to report that the company's NAV per ordinary share rose by 21.5% on a net dividends reinvested basis with debt at fair value, our key performance measure. This was marginally ahead of the composite benchmark index - 70% FTSE World Ex-UK and 30% FTSE All-Share Index - which rose by 21.1% on a total return basis over the period," company says. "This marks a third year of outperformance against the benchmark. It is particularly pleasing to see this outperformance in the radically different market conditions of these years." Proposes final dividend of 6.05p, taking total dividend to 20.15p, up from 20.06p year before.

----------

Hemogenyx Pharmaceuticals PLC - London-based developer of drugs for blood diseases - Receives notification from US Food & Drugs Administration that proposed pre-investigational new drug meeting for its lead product candidate chimeric antigen receptor T-cells is to be deferred until May 2022. Notes US regulator's general policy to prioritise work on Covid. "The deferment of the meeting is not causing any delay in the development of the product candidate. In the meantime, the process will be dealt with by written responses by the FDA to a submission which is now being refined," company says.

----------

Crossword Cybersecurity PLC - London-based cyber security and risk-focused technology commercialisation company - Says the IASME Consortium Ltd, the UK's government cyber essentials partner selects Rizikon Assurance as the core platform to support a new Maritime Security certification. "IASME, has a proven record for delivering recognised certifications and is scaling its portfolio to include a new Maritime Cyber Baseline scheme. The Maritime Cyber Baseline scheme provides an affordable and practical way for shipping operators and vessel owners to improve their cyber security to reduce the likelihood of a cyber-attack disrupting their day-to-day operations," company explains.

----------

Silver Bullet Data Services Group PLC - London-based provider of digital transformation services and products - Highlights number of recent 4D context outcomes engine engagements with its flagship digital marketing product. Notes AXA UK, Renault and Greene King among firms using 4D context outcomes engine. Chief Executive Ian James says: "We are delighted to have secured these project wins through our 4D technology platform delivering business advantage and market leading outcomes for clients. 4D is a product designed for the post-cookie era, and an important part of Silverbullet's overall data offering. To work with such prestigious brands and companies to improve marketing outcomes demonstrates the long-term value that 4D brings to the advertising ecosystem. I look forward to further updating the market in due course."

----------

Hydrogen Utopia International PLC - London-based company specialising in turning non-recyclable mixed waste plastic into carbon-free fuels - Acknowledges no agreement exists with Mitsubishi Heavy Industries Ltd. In mid-January, said it signed a LoI with the Japanese firm for Mitsubishi to review technology and explore the commercial opportunities for developing waste plastic to hydrogen facilities. Company on Wednesday says: "HUI continues to explore opportunities in Japan and is hopeful that it may work with MHI in the future."

----------

i(x) Net Zero PLC - St Helier, Jersey-registered investment firm focused on energy transition and sustainability - Investee WasteFuel launches new WasteFuel Agriculture product. Company says: "Using proven technologies, WasteFuel Agriculture will convert farm waste into low-carbon fuels, such as renewable natural gas and bio-methanol, which can be used in land and marine transport. Compared to conventional fuels, WasteFuel aims for its fuels to cut greenhouse gas emissions by up to 90%. In addition to producing low-carbon fuel, WasteFuel Agriculture gives farms the ability to sell biogenic farm waste that would otherwise decompose and release methane and carbon dioxide."

----------

Lekoil Ltd - London-based oil and gas exploration and production company with projects focused in Nigeria and West Africa - Says Olalekan Akinyanmi applies to restrain company from acting on resolutions 8 and 9 from annual general meeting. "The notice of motion is expected to be heard in early to mid-March 2022. The company considers that the claim is entirely without merit and will defend the claim in the normal manner. Further updates in relation to the claim will be made as appropriate," company adds.

----------

Power Metal Resources PLC - London-based metal discoveries company with projects focused in Africa, Australia and North America - Says focus for majority-owned subsidiary Golden Metal Resources Ltd remains preparing London listing. Chief Executive Paul Johnson adds: "Our preparatory work has revealed positive findings with a growing target base for potential resource expansion at Pilot Mountain project and emboldening our belief in the potential of Golconda, Garfield and Stonewall projects."

----------

Aura Energy Ltd - Australia-based minerals company with polymetallic and uranium projects in Europe and Africa - Notes JORC compliant resource estimate for 18.4 million pounds vanadium contained within its Tiris Uranium deposits in Mauritania. Acting Chief Executive Will Goodall says: "The inclusion of vanadium in the resource estimates for Tiris gives Aura a wonderful opportunity to explore further operating cost reductions through addition of vanadium pentoxide as a by-product to uranium. This vanadium resource estimate provides the initial step to further optimise the low cost Tiris project and we are excited by the prospect of further enhancing the project in this way."

----------

Contango Holdings PLC - natural resource development company - Says results from aero-magnetic studies 100%-owned Garalo-Ntiela gold project in Mali yield "multiple high-grade potential target zones". Notes 50% of the ongoing induced polarisation survey has been completed. Says IP survey, coupled with the results of the aero-magnetic studies and historic drilling will enable the company to finalise its 2022 drill programme, intended to firm up the targeted resource of 1.8 million ounces to 2 million ounces gold. Chief Executive Carl Esprey says: "Given the potential scale of Garalo-Ntiela, the Company has benefited from heightened interest in the project by third parties. Whilst these discussions are at a relatively early stage, it certainly highlights the optionality we have with this project and the international interest which has been generated by our work so far."

----------

Helium One Global Ltd - London-based exploration & development company - Pretax loss in year to June 30 widens to USD5.2 million from USD2.3 million loss in same period year before. Administrative expenses rises to USD3.0 million from USD2.3 million and notes USD2.3 million impairment on acquisition in the period, which was not incurred year prior. Does not generate revenue in either period. Chair Ian Stalker says: "The period to June 2021 has been transformational for Helium One as we continue along the road to seeking a globally strategic discovery. Helium remains in critical short supply and a new source of primary helium without associated hydrocarbon production is required to balance the market. Helium One has the capacity to discover this new source and become a strategic player in resolving long term supply issues."

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
25 Apr 2024 12:19

EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
29 Feb 2024 14:04

Hemogenyx Pharmaceuticals raises money for leukaemia treatment

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Thursday said it has raised GBP3.3 million through a placing.

Read more
16 Feb 2024 11:27

Hemogenyx shares rise on potential for CBR to treat brain diseases

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Friday said research has shown that its proprietary chimeric bait receptor can be delivered into the brain through programmed microglial cells and could be used for the treatment of brain cancers and some neurodegenerative diseases.

Read more
14 Feb 2024 10:14

Hemogenyx says CBR can be used intranasally to treat viral infections

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Wednesday said its chimeric bait receptor can be delivered intranasally in the form of messenger RNA for the "potential" treatment of airborne viral infections.

Read more
9 Feb 2024 10:00

IN BRIEF: Hemogenyx shares surge as FDA lifts Hemo-Car-T trial hold

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - US Food & Drug Administration has lifted clinical hold on company's investigational new drug application for Hemo-Car-T to treat acute myeloid leukemia. FDA placed therapy on clinical hold in July due to a splicing deficiency during manufacture of the lentivirus used to produce Car-T cells. Hemogenyx in August produced a "detailed plan, supported by laboratory tests" to address FDA's concerns, which was accepted the following month.

Read more
2 Feb 2024 10:44

IN BRIEF: Hemogenyx hails US patent application progress

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - Celebrates as patent application is allowed by the US Patent & Trademark Office. The patent is for the process of eliminating hematopoietic stem cells or hematopoietic progenitors in a patient using bi-specific antibodies.

Read more
16 Jan 2024 11:13

Hemogenyx Pharmaceuticals sends complete response on HEMO-CAR-T to FDA

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Tuesday said it submitted a complete response to the previously announced clinical hold of the investigational new drug application to the US Food & Drug Administration.

Read more
8 Jan 2024 10:56

Hemogenyx Pharmaceuticals completes process qualification run

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday said it completed a process qualification run.

Read more
28 Nov 2023 16:53

TRADING UPDATES: Upland Resources completes technical study at Sarawak

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
27 Nov 2023 10:52

Hemogenyx shares up as says CBR platform a potential cancer treatment

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday said its chimeric based receptor platform could "potentially" be used to treat cancer and viral diseases.

Read more
15 Nov 2023 15:43

Hemogenyx Pharmaceuticals completes lentivirus re-manufacture

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Wednesday said it has completed the re-manufacturing of an improved lentivirus devoid of splice variants.

Read more
28 Sep 2023 14:24

EARNINGS: Dar Global profit multiplies, Hemogenyx loss widens

(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 Sep 2023 14:37

TRADING UPDATES: Avingtrans buys Adaptix, TPXimpact sells Questers

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
18 Sep 2023 13:00

Hermogenyx shares soar on new partnership with Prevail Partners

(Sharecast News) - Shares in biopharma group Hemogenyx surged on Monday after the company received a $0.83m investment from Prevail Partners as it continues to work on its planned clinical trial for leukaemia treatment.

Read more
14 Sep 2023 14:31

Hemogenyx Pharma says US FDA accepts Hemo-Car-T clinical hold lift plan

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Thursday said the US Food & Drug Administration has accepted its plan to address concerns which sparked a clinical hold on its chimeric antigen receptor T-cell or Hemo-Car-T therapy.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.